fda warning letters compounded semaglutide telehealth 2024 2025 September 15, 2025: company must stop implying its GLP-1 is FDA-approved, warns – Partnership for Safe Medicines U.S. FDA sends drug advertising

Patients with complex comorbidities or polypharmacy concerns should disclose these thoroughly during their initial consultation

However, its important to understand that retatrutide is not yet FDA approved

If fatigue persists beyond the first few weeks, ask your provider to check your B12 and iron levels

RCT, randomized controlled trial

Nutrition on GLP-1 therapy should emphasize omega-3 fatty acids, polyphenol-rich foods, and adequate protein to support immune function and tissue repair

For people with diabetes, the American Diabetes Association recommends checking both eGFR and urine albumin-to-creatinine ratio at least annually, or more frequently with existing kidney disease